• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ebola-affected countries receive NIH support research training support

Ebola-affected countries receive NIH support research training support

October 31, 2016
CenterWatch Staff

The recent Ebola epidemic in West Africa highlighted the need for better global preparedness and response to disease outbreaks. To help address that need in Guinea, Liberia and Sierra Leone—the countries most affected by the epidemic—the NIH has established a new program to strengthen the research capacity to study Ebola, Lassa fever, yellow fever and other emerging viral diseases. In the initiative’s first funding round, NIH’s Fogarty International Center is awarding grants to four U.S. institutions that will partner with West African academic centers to design training programs for their scientists and health researchers.

The collaborations aim to develop research training proposals that would strengthen the skills required to evaluate vaccines, develop new diagnostic tests and treatments, and identify the most effective intervention strategies for disease outbreaks. These planning grants, totaling $200,000, are intended to help institutions prepare to compete for larger, longer-term Fogarty grants to implement research training programs.

“We hope these awards will catalyze efforts to identify existing resources and plan to address development of sustainable research capacity in the countries that suffered so horribly from Ebola,” said Fogarty Director Roger I. Glass, M.D., Ph.D. “By training local researchers in epidemiology and lab skills, and helping them form networks with U.S. scientists, we believe future disease outbreaks can be better contained.”

This new Fogarty training initiative was developed in response to a World Health Organization (WHO) assessment that noted weak health systems, poor disease surveillance and inadequate research and development resources were among the factors contributing to the 2014-2016 Ebola epidemic. The program targets the neighboring countries of Guinea, Liberia and Sierra Leone, where more than 28,000 Ebola cases and 11,000 deaths were reported, according to the WHO.  The three countries are recovering from conflicts and have fragile health systems. In the first funding round, awards are supporting one partnership in Liberia and three collaborations in Sierra Leone.

Yale University in Connecticut is partnering with the University of Liberia to design a research training program focused on epidemiology and predictive transmission modeling. Based in the capital city of Monrovia, the university is Liberia’s flagship institution for higher education and has a medical school with roughly 200 students. The lead investigators from both countries collaborated on research during the Ebola crisis.

Scientists from Duke University in North Carolina are building on existing relationships with colleagues at the University of Sierra Leone’s College of Medicine and Allied Health Sciences (COMAHS), located in the capital city of Freetown. Their joint training plan intends to focus on clinical research for local scientists so they can quickly implement trials for vaccines and therapeutics during a disease outbreak. COMAHS, founded in 1988, is the country’s first medical school and has 1,500 students. Nearby Connaught Hospital, a 120-bed facility, is a partner on the project.

COMAHS is also the collaborating institution on an award to Vanderbilt University, Nashville, Tennessee. This project aims to plan a research capacity building program in implementation science and clinical trial management to address Ebola, Lassa fever and other viral hemorrhagic fevers. The primary training site will be the Kenema Government Hospital, located in a region with the world’s highest incidence of Lassa fever. The hospital, which contains the country’s only Lassa fever laboratory, has a previously established research relationship with Tulane University in Louisiana. A Tulane scientist will also collaborate on the training project.

Another investigator at Tulane University is receiving funding to assess the research training needs of Sierra Leone’s Njala University, which graduates a substantial number of allied health workers. Its main campus is in Njala, about 125 miles east of the capital, and includes a 50-bed hospital and laboratories that serve the city and surrounding communities. A second campus, about 35 miles away in Bo, has two health centers. The project aims to develop a strategic plan for research training, which may include distance learning opportunities since Njala has already invested in computer labs and high-speed internet.

Fogarty has issued a second call for applications to support further awards under the program, with a deadline of Feb. 22, 2017.

2016 awards

  • Duke University: Planning Grant for Emerging Virus Research Training in Sierra Leone
  • Tulane University: Preventing the next storm: Building research and epidemic response capability at Njala University, Sierra Leone
  • Vanderbilt University: Research Capacity Building in Post Ebola Countries
  • Yale University: Sustainable capacity in Liberia for informing surveillance and response through modeling, biostatistics and computational tools

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing